Astaxanthin - MeraAlternative Names: AstaFactor
Latest Information Update: 20 Sep 2002
At a glance
- Originator Mera Pharmaceuticals
- Class Anti-inflammatories; Antineoplastics; Xanthophylls
- Mechanism of Action Antioxidants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cardiovascular disorders; Exercise-induced asthma; Macular degeneration
Most Recent Events
- 20 Sep 2002 Aquasearch is now called Mera Pharmaceuticals
- 11 Jun 2002 No development reported - Clinical-Phase-Unknown for Exercise-induced asthma in USA (PO)
- 11 Jun 2002 No development reported - Clinical-Phase-Unknown for Macular degeneration in USA (PO)